Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/DARZALEX

Authorized

STANDARD

DARZALEX

Janssen Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 20915aac64924c29
Company: Janssen Inc
Type: Standard

Approval Details

Approval Id: 20915aac64924c29
Drug Approval Canada Name: DARZALEX
Product Name: DARZALEX
Status: Marketed
Status Date: 2016-07-12
Original Market Date: 2016-07-12
Din: 02455951
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 10:00.00
Atc Original: L01FC01 DARATUMUMAB
Atc Name: l 01 fc 01
Aig Number: 0158231001
Company Name: Janssen Inc
Company Address: 19 Green Belt Drive, Toronto, Ontario, Canada, M3C 1L9
Company Detail Path: /organization/janssen-inc

Company Information

Pharmaceutical Company Name: Janssen Inc.
Name En: Janssen Inc.
Country Name: Canada
Province Name: Ontario
City Name: north york,ontario,country_ca
Address: 19 Green Belt Dr

Active Ingredients

DARATUMUMAB

100 MG / 5 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

20915aac64924c29

Type

Standard

Back to Health Canada Approvals

DARZALEX - Health Canada Drug Approval Details